Advertisement

Ceftazidime Injection

[01 December 2014]

Products Affected - Description

Ceftazidime vials
Fortaz injection, Covis
500 mg vials, packages of 10 (NDC 24987-0377-10)
1 gm vials, package of 10 (NDC 24987-0378-10)
1 gm TwistVials, packages of 25 (NDC 24987-0434-00)
2 gm vials, packages of 10 (NDC 24987-0379-34)

2 gm TwistVials, packages of 10 (NDC 24987-0435-00)
 
Tazicef injection, Hospira
1 gm vials, packages of 25 (NDC 00409-5082-16)

Reason for the Shortage

  • Pfizer discontinued all of its ceftazidime injection products in late-November, 2011.
  • West-Ward discontinued all of its ceftazidime injection products in January 2012.
  • Hospira has ceftazidime on shortage due to manufacturing delays.
  • Covis purchased all rights to Fortaz from GlaxoSmithKline. Covis began changing NDC numbers in December 2012.
  • Sagent had ceftazidime injection on shortage due to increased demand for the product.
  • WG Critical Care launched ceftazidime 1 gram vials in July 2013 and product is available at wholesalers. Ceftazidime 2 gram and 6 gram presentations were launched in August 2013.

Available Products

Ceftazidime vials
Fortaz injection, Covis
6 gm vials, packages of 6 (NDC 24987-0382-37)
 
Tazicef injection, Hospira
1 gm ADD-Vantage vials, packages of 25 (NDC 00409-5092-16)
2 gm vials, packages of 10 (NDC 00409-5084-11)
2 gm ADD-Vantage vials, packages of 10 (NDC 00409-5093-11)
6 gm vials, packages of 10 (NDC 00409-5086-11)

Ceftazidime injection, Sagent
1 gm vials, packages of 25 (NDC 25021-0127-20)
2 gm vials, packages of 10 (NDC 25021-0128-50)
6 gm vials, packages of 6 (NDC 25021-0129-99)
 
Ceftazidime injection, Sandoz
1 gm vials, packages of 25 (NDC 00781-3177-96)
2 gm, vials, packages of 10 (NDC 00781-3178-95)
6 gm vials, packages of 6 (NDC 00781-3179-86)
 
Ceftazidime injection, WG Critical Care
1 gram vials, package of 25 (NDC 44567-0235-25)
2 gram vials, package of 10 (NDC 44567-0236-10)
6 gram vials, package of 6 (NDC 44567-02375-06)

Ceftazidime premixed bags
Fortaz solution, Covis
1 gm/50 mL premixed bag (NDC 24987-0412-00)
2 gm/50 mL premixed bag (NDC 24987-0413-00)

Ceftazidime injection, B. Braun Medical
1 gm/50 mL premixed bag (NDC 00264-3143-11)
2 gm/50 mL premixed bag (NDC 00264-3145-11)

Estimated Resupply Dates

  • Covis has all Fortaz presentations except the 6 gram vials on back order and the company estimates a release date of January 2015.
  • Hospira has Tazicef 1 gram vials on back order and the company estimates a release date of December 2014.

Related Shortages

Updated

December 1, 2014; November 21, 2014; November 4, 2014; October 3, 2014; September 5, 2014; August 15, 2014; August 1, 2014; July 17, 2014; July 3, 2014; June 24, 2014; June 3, 2014; April 24, 2014; April 2, 2014; March 3, 2014; February 24, 2014; January 24, 2014; January 6, 2014; December 20, 2013; December 4, 2013; November 13, 2013; October 14, 2013; October 10, 2013; August 30, 2013; July 18, 2013; June 13, 2013; May 20, 2013; April 24, 2013; April 17, 2013; March 8, 2013; February 13, 2013; January 28, 2013; January 14, 2013; December 24, 2012; November 30, 2012; October 22, 2012; September 27, 2012; August 9, 2012; July 25, 2012; July 5, 2012; June 12, 2012; June 1, 2012; May 16, 2012; April 24, 2012; March 30, 2012; February 8, 2012; January 10, 2012; December 21, 2011; November 29, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement